FilingReader Intelligence

Kehua Bio-Engineering gets hepatitis C diagnostic registration

July 26, 2025 at 05:30 AM UTCBy FilingReader AI

Shanghai Kehua Bio-Engineering Co., Ltd. has obtained a medical device registration certificate from the National Medical Products Administration for its "Hepatitis C Virus Antibody Quality Control Product."

The certificate is valid from July 24, 2025, to July 23, 2030. The quality control product is designed for use with the company's existing Hepatitis C Virus Antibody Detection Reagent Kit to ensure quality control for hepatitis C virus antibody detection.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:002022Shenzhen Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Shanghai Kehua Bio-Engineering publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →